# (PQ1) The role of cell-to-cell variation in the penetrance of heritable mutant RAS hypodermal neoplasias > **NIH NIH R01** · UNIVERSITY OF WASHINGTON · 2020 · $368,523 ## Abstract Project Summary: Our goal is to provide answers to the question: “What molecular mechanisms influence disease penetrance in individuals who inherit a cancer susceptibility gene?”. We plan to answer this question in terms of genetics and cell biology. More specifically, we plan to identify which genes influence the penetrance of RAS-driven neoplasia, and then observe how these genes alter the stereotyped program of gene expression and cell division by directly observing gene expression and cell division with quantitative light microscopy. Children with Noonan or Costello syndromes are born with mutations in RAS, the most common oncogene. Some, but not all of these individuals develop cancer. RAS-driven cancers are notoriously difficult to treat. Current anti-HSP90 clinical trials show some promise, but the drugs are toxic. We have evidence that other chaperones may be suitable targets for suppressing Ras-based cancer formation. We have evidence that the molecular mechanism that influences Ras-driven neoplasia penetrance is the epigenetically heritable ability to express more or maintain more biologically active molecules of protein per unit gene. In the proposed research, we will study isogenic C. elegans with a Ras gain of function allele that results in incompletely penetrant hypodermal neoplasia. When these animals inherit a gain of function mutation in their sole Ras homolog, let-60, just like children with Noonan syndrome, some of them will develop neoplasias. About 90% of Ras oncogene bearing worms will acquire 1-4 hypodermal neoplasias during development, in response to conserved, cancer- related EGF, Notch and WNT signaling pathways. In worms with wild-type Ras, these pathways would normally control organogenesis of the vulva. The initial manifestation of neoplasia happens reliably, at the same time during development, over and over – right when the signal for vulva development happens. We have a system wherein we know exactly where and when to look, so we can see exactly what happens in cells that may or may not become neoplastic. We will perform a reverse genetic screen to identify genes that affect neoplasia. We will watch how these genes change the series of normally well-coordinated gene expression events that cause cell proliferation and transform cell fate by measuring gene expression while it happens in living cells. Our specific central hypothesis is that animals that do develop neoplasias have epigenetic differences in chaperone expression that cause an increase in translation efficiency, resulting in a higher effective gene dosage of the Ras gain of function allele, and that in turn, results in the manifestation of neoplasia. We provide strong evidence for this hypothesis in the approach. ## Key facts - **NIH application ID:** 9989803 - **Project number:** 5R01CA219460-03 - **Recipient organization:** UNIVERSITY OF WASHINGTON - **Principal Investigator:** Alexander Richard Mendenhall - **Activity code:** R01 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2020 - **Award amount:** $368,523 - **Award type:** 5 - **Project period:** 2018-09-01 → 2023-08-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/9989803 ## Citation > US National Institutes of Health, RePORTER application 9989803, (PQ1) The role of cell-to-cell variation in the penetrance of heritable mutant RAS hypodermal neoplasias (5R01CA219460-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9989803. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*